Orphan designation: eltanexor Treatment of myelodysplastic syndromes, 21/06/2022 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 11 May 2026 - 9:07

Orphan designation: eltanexor Treatment of myelodysplastic syndromes, 21/06/2022 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2641

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters